Over 10 Million Merchants Join Five Fortune Card Campaign on Alipay Platform to Further Engage With Consumers Ahead of CNY
21.1.2023 21:05:00 EET | Business Wire | Press release
Over 10 million brands and merchants in China joined Alipay’s signature annual Five Fortune Card Collection campaign for the 2023 Chinese New Year, ramping up digital efforts to attract and engage mobile-savvy consumers, as Chinese consumers gear up for the most important festival of the year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230121005044/en/
A user trying to collect a fortune card by scanning the Chinese character “fu” with AR scan feature in Alipay app (Photo: Business Wire)
This year’s campaign, from January 10, 2023 to January 21, attracted more than 30,000 blue chip and emerging international and domestic brands and over 10 million small and micro business participants seeking to enhance their interaction with Chinese consumers in anticipation of the Spring Festival. This represented a nearly 30 times increase in the number of brands that participated in the campaign last year.
“As an open platform, Alipay is committed to opening up products and technologies to facilitate merchants’ digital transformation. We have also introduced Five Fortune Card IP-related resources to our partners,” said Yongming He, General Manager of the Alipay Ecosystem Development Business Unit and Vice President of Ant Group. “We are glad to see a growing number of brands and merchants participating in the Alipay Five Fortune Card Collection campaign to enhance engagement with users and improve operational efficiency by leveraging digital tools, including mini program and livestreaming, on the Alipay platform.”
Initially launched in 2015, Alipay's Five Fortune Card Collection campaign is an annual event before the Chinese New Year. Users collect digital fortune cards by using the Alipay app's AR scan feature and participating in merchant campaigns, among various ways to win a fortune card. These cards represent good wishes and can be converted into monetary rewards.
This year, for the first time, users can receive a limited-edition digital collectible featuring Chinese intangible cultural heritage, including shadow puppetry, paper-cut and copper sculpture, after successfully obtaining five fortune cards in the campaign.
Users can win a fortune card when they scan the red envelope QR code each time at the outlets of the 10 million participating merchants. They may also obtain cards by logging into Alipay mini programs or by watching livestreams of more than 30,000 participating brands on Alipay. Through these livestreams, brands distributed fortune cards to participants, introduced their products and services, and gave out preferential benefits to build connections with mobile-savvy Chinese consumers.
Merchants and brands have seen significant digital engagement through their participation in the Alipay campaign, with millions of views from livestreaming. On January 11, No. 1 Job Club, a job search service provider, saw 20 million visits to their livestreaming on Alipay platform. On the same day, Yunchongbao, a pet service provider, witnessed 50 million visits to their Alipay livestream. And on January 15, the NBA attracted over 12 million visits to their Alipay livestream which was moderated by several local basketball influencers. These numbers demonstrate the success of the campaign in attracting digital participation from merchants and brands, as reflected in the large livestream audience engagement on the Alipay platform.
Pop-Mart, a culture and entertainment company that is best known for art and collectible toys who introduced the idea of "blind box”, attracted three million visits to their Alipay mini-program six days into the campaign, with its transaction volume through the Alipay platform increasing 300% compared with that of last month.
About Alipay
In the evolving digital era, Alipay has transformed from a trusted payment tool to an open platform for businesses, institutions, service providers, and other partners. Business partners in various industries utilize Alipay to offer consumers a safe and convenient payment experience. Through digital operations on the Alipay platform, business partners can communicate and provide various commercial and daily life digital services for their clients via Alipay mini programs, lifestyle accounts, and IoT, along with other tools available. Currently, there have been over 80 million businesses serving more than one billion consumers via Alipay’s open platform services.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230121005044/en/
Contact information
Media Enquiry
Bell Wang
yixing.wl@antgroup.com
+86 138 1038 5201
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors9.9.2026 16:45:00 EEST | Press release
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) today announced that Dr. Kunihiro Hattori (former Senior Fellow of Chugai), Dr. Takehisa Kitazawa (Deputy Head of Research Division, Chugai), and Dr. Tomoyuki Igawa (Head of Research Division, Chugai), who led the creation of Hemlibra (emicizumab), a treatment for hemophilia A, have been awarded the Lasker-DeBakey Clinical Medical Research Award, one of the world's most prestigious scientific honors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909923883/en/ From left: Dr. Kitazawa, Dr. Hattori, and Dr. Igawa Hemophilia A is caused by a deficiency of coagulation Factor VIII, one of the proteins required for normal blood clotting. When activated, Factor VIII serves as a bridge that facilitates the activation of Factor X by activated Factor IX on the surface of activated platelets. The award recognizes the unconventional concept of replacing this function of Factor VIII with a
AMCS Appoints Richard Humphrey as Chief Product and Technology Officer9.9.2026 16:00:00 EEST | Press release
AMCS, a leading technology provider for the waste and recycling industry, today announced the appointment of Richard Humphrey as Chief Product and Technology Officer. Based in Boston, Humphrey will lead the company’s global product organisation. Humphrey brings more than 25 years of experience developing software for construction and other complex industrial environments. He joins AMCS as the company deepens its focus on waste and recycling and expands the role of AI across its platform. Most recently, Humphrey served as Chief Product and Technology Officer at Contruent, where he led product strategy for a construction cost-management platform used on major capital programmes. He previously held vice president roles at Bentley Systems and B2W Software. Earlier in his career, he spent more than a decade at Autodesk, where he led its Civil Design and Construction software business as Senior Director. “Richard understands what it takes to build software for industries where the work is ex
BBH Launches a New Technology Business, Braid, Solving for Intelligent Data Transformation9.9.2026 15:45:00 EEST | Press release
Brown Brothers Harriman (BBH) today announced the launch of a new technology affiliate, Braid LLC, focused on solving enterprise data transformation for financial services. Braid offers an AI-native data transformation platform that gives firms a scale solution to transform, connect, and manage their data with confidence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909294398/en/ Braid empowers teams to build, automate, and oversee reliable production-grade data transformations in a fraction of the time typically required today. Instead of requiring engineers to build data automations, Braid allows business users to describe their needs in natural language that AI agents use to build intelligent data transformations that are transparent and fully auditable. Braid’s enterprise-grade engine then processes and delivers those data transformations in a controlled and deterministic environment. Built by financial services exp
LTM Collaborates with IBM and Red Hat on Lightwell to Advance AI-Driven Open-Source Software Remediation9.9.2026 15:30:00 EEST | Press release
LTM, the Business Creativity partner to the world's largest enterprises, today announced that it has collaborated with IBM and Red Hat on Lightwell to help enterprises safeguard the open-source software supply chain through AI-driven vulnerability remediation. As AI accelerates the discovery of software vulnerabilities, organizations must move beyond detection-focused approaches and adopt enterprise-scale remediation strategies that enable rapid risk mitigation without disrupting business-critical applications. Lightwell’s approach of delivering validated fixes for production environments aligns with LTM's aim of helping customers build secure, resilient, and operationally efficient software supply chains. By combining AI-powered remediation capabilities with enterprise-grade validation and deployment support, Lightwell aims to help organizations address security challenges across increasingly complex open-source ecosystems. Building on its long-standing status as an IBM Platinum Partn
New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life9.9.2026 15:24:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the New England Journal of Medicine published results from two Phase 3 studies evaluating oveporexton (ORZEYFUL), an oral orexin receptor 2 (OX2R) agonist, in people with narcolepsy type 1 (NT1).1 Oveporexton is the first and only medicine to treat the underlying cause of NT1. "People living with narcolepsy type 1 face persistent symptoms across the day and night, which can impact many aspects of daily life,” said Emmanuel Mignot, M.D., Ph.D., principal investigator for the FirstLight (TAK-861-3001) Phase 3 study. “The newly published Phase 3 data reinforce the potential of oveporexton to transform how we approach narcolepsy type 1 in clinical practice, shifting from managing individual symptoms to treating the disease itself.” NT1 is a chronic, rare neurological disease driven by orexin deficiency. As a result, people experience a range of daytime and nighttime symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom